Previous 10 | Next 10 |
2024-04-13 13:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 PR Newswire Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations...
2024-03-24 14:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 PR Newswire CAMBRIDGE, Mass. , March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biophar...
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire Well-capitalized with operating runway anticipated into 2027 CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewsw...
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 PR Newswire CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted thera...
2024-02-23 18:33:26 ET More on Nuvalent Nuvalent: Strong Data, But Properly Valued Nuvalent announces 'OnTarget 2026' operating plan; aims for first approved product in 2026 Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuvalent...
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors PR Newswire Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with...
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference PR Newswire CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisel...
News, Short Squeeze, Breakout and More Instantly...
2024-06-13 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CAMBRIDGE, Mass. , May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapi...
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 PR Newswire CAMBRIDGE, Mass. , May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therap...